• Profile
Close

Isoniazid preventive therapy in HIV-infected pregnant and postpartum women

New England Journal of Medicine Oct 09, 2019

Gupta A, Montepiedra G, Aaron L, et al. - Via a multicenter, double-blind, placebo-controlled, noninferiority trial, researchers randomized pregnant women with HIV infection who are receiving antiretroviral therapy, to receive isoniazid preventive therapy for 28 weeks, started either during pregnancy (immediate group) or at week 12 following delivery (deferred group) in order to ascertain safety, efficiency, and relevant timing of isoniazid therapy to counter tuberculosis in such woman. A total of 956 women were recruited. Six women acquired tuberculosis. A greater incidence of an event incorporated in the composite adverse pregnancy outcome (stillbirth or spontaneous abortion, low birth weight in an infant, preterm delivery, or congenital anomalies in an infant) was noted in the immediate group vs the deferred group. Thus, in comparison with those related to the beginning of therapy during the postpartum period, the risks correlated with the beginning of isoniazid preventive therapy during pregnancy seemed to be greater.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay